Cartesian Therapeutics, Inc announced it has entered into a Securities Purchase Agreement of 3,563,247 shares of the common stock at a price per share of $20 for gross proceeds $71,264,940, and 2,937,903 shares of the Company?s Series B Non-Voting Convertible Preferred Stock at a price per share of $20, for gross proceeds $58,758,060 for an aggregate purchase price of approximately $130,023,000 on July 2, 2024. The closing of the Private Placement is expected to occur on July 3, 2024. The securities to be issued and sold to the Purchasers under the Purchase Agreement will not be registered under the Securities Act of 1933, as amended (the ?Securities Act?) in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws.